Infinium Pharma

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE0MRE01011
  • NSEID: INFINIUM
  • BSEID:
INR
210.50
3.75 (1.81%)
BSENSE

Jun 10, 03:30 PM

BSE+NSE Vol: 500

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationAnnual Results
Results Snapshot
Figures in Cr
Consolidate Annual Results
Mar'26
Mar'25
Mar'24
Mar'23
Mar'22
Net Sales
189.63
155.71
135.66
114.22
99.12
Other Operating Income
0.00
0.00
0.00
0.00
0.00
Total Operating income
189.63
155.71
135.66
114.22
99.12
Raw Material Cost
126.98
109.29
98.83
71.53
54.22
Purchase of Finished goods
20.95
14.33
9.22
8.64
24.14
(Increase) / Decrease In Stocks
0.62
-6.02
-4.95
0.40
-1.62
Employee Cost
8.67
7.43
5.91
5.37
3.54
Power Cost
0.00
0.00
0.00
0.00
0.00
Manufacturing Expenses
0.00
0.00
0.00
0.00
0.00
Selling and Distribution Expenses
0.00
0.00
0.00
0.00
0.00
Other Expenses
10.85
14.26
8.12
12.24
8.81
Total Expenditure (Excl Depreciation)
168.07
139.29
117.13
98.18
89.09
Operating Profit (PBDIT) excl Other Income
21.56
16.42
18.53
16.04
10.03
Other Income
2.14
2.12
1.54
1.35
0.93
Operating Profit (PBDIT)
23.70
18.54
20.07
17.39
10.96
Interest
2.80
3.67
2.19
3.10
1.70
Exceptional Items
0.00
0.00
0.00
0.00
0.00
Gross Profit (PBDT)
20.90
14.87
17.88
14.29
9.26
Depreciation
3.06
3.29
2.67
1.34
0.63
Profit Before Tax
17.84
11.57
15.21
12.95
8.63
Tax
3.64
3.73
3.71
3.14
1.95
Provisions and contingencies
0.00
0.00
0.00
0.00
0.00
Profit After Tax
14.20
7.84
11.50
9.82
6.69
Extraordinary Items
0.00
0.00
0.00
0.00
0.00
Prior Period Expenses
0.00
0.00
0.00
0.00
0.00
Other Adjustments
0.00
0.00
0.00
0.00
0.00
Net Profit
14.20
7.84
11.50
9.82
6.69
Share in Profit of Associates
0.00
0.00
0.00
0.00
0.00
Minority Interest
-2.05
0.30
-0.20
-0.33
-0.58
Other related items
0.00
0.00
0.00
0.00
0.00
Consolidated Net Profit
12.15
8.15
11.30
9.49
6.11
Equity Capital
15.58
15.58
13.92
5.08
1.02
Face Value
10.0
10.0
10.0
10.0
10.0
Reserves
105.46
93.88
44.86
17.48
12.09
Earnings per share (EPS)
7.8
5.23
8.12
18.68
11.98
Diluted Earnings per share
7.8
5.6
8.12
18.67
60.07
Operating Profit Margin (Excl OI)
11.37%
10.55%
13.66%
14.04%
10.12%
Gross Profit Margin
11.02%
9.55%
13.18%
12.51%
9.34%
PAT Margin
7.49%
5.04%
8.48%
8.6%
6.75%
Public Share Holdings (%)
0.0%
0.0%
0.0%
0.0%
0.0%
Pledged Promotor Holding (%)
0.0%
0.0%
0.0%
0.0%
0.0%
Annual Analysis Highlights
stock-summary

Net Sales

YoY Growth in year ended Mar 2026 is 21.78% vs 14.78% in Mar 2025

stock-summary

Consolidate Net Profit

YoY Growth in year ended Mar 2026 is 49.08% vs -27.88% in Mar 2025

stock-summary

Operating Profit (PBDIT) excl Other Income

YoY Growth in year ended Mar 2026 is 31.30% vs -11.39% in Mar 2025

stock-summary

Interest

YoY Growth in year ended Mar 2026 is -23.71% vs 67.58% in Mar 2025

stock-summary

Operating Profit Margin (Excl OI)

YoY Growth in year ended Mar 2026 has improved from Mar 2025

Compare Annual Results Of Infinium Pharma With
Markets Mojo
Figures in Cr
Consolidate Annual Results
Markets Mojo
Markets Mojo
Change(INR)
Change(%)
Net Sales
189.63
197.77
-8.14
-4.12%
Other Operating Income
0.00
0.00
0.00
Total Operating income
189.63
197.77
-8.14
-4.12%
Raw Material Cost
126.98
94.35
32.63
34.58%
Purchase of Finished goods
20.95
0.00
20.95
(Increase) / Decrease In Stocks
0.62
7.42
-6.80
-91.64%
Employee Cost
8.67
34.69
-26.02
-75.01%
Power Cost
0.00
0.00
0.00
Manufacturing Expenses
0.00
0.00
0.00
Selling and Distribution Expenses
0.00
0.00
0.00
Other Expenses
10.85
41.72
-30.87
-73.99%
Total Expenditure (Excl Depreciation)
168.07
178.18
-10.11
-5.67%
Operating Profit (PBDIT) excl Other Income
21.56
19.59
1.97
10.06%
Other Income
2.14
3.11
-0.97
-31.19%
Operating Profit (PBDIT)
23.70
22.70
1.00
4.41%
Interest
2.80
3.50
-0.70
-20.00%
Exceptional Items
0.00
0.00
0.00
Gross Profit (PBDT)
20.90
19.20
1.70
8.85%
Depreciation
3.06
7.22
-4.16
-57.62%
Profit Before Tax
17.84
11.98
5.86
48.91%
Tax
3.64
2.19
1.45
66.21%
Provisions and contingencies
0.00
0.00
0.00
Profit After Tax
14.20
9.80
4.40
44.90%
Extraordinary Items
0.00
0.00
0.00
Prior Period Expenses
0.00
0.00
0.00
Other Adjustments
0.00
0.00
0.00
Net Profit
14.20
9.80
4.40
44.90%
Share in Profit of Associates
0.00
0.00
0.00
Minority Interest
-2.05
-0.16
-1.89
-1,181.25%
Other related items
0.00
0.00
0.00
Consolidated Net Profit
12.15
9.64
2.51
26.04%
Equity Capital
15.58
13.56
2.02
14.90%
Face Value
10.00
10.00
0.00
Reserves
105.46
26.99
78.47
290.74%
Earnings per share (EPS)
7.80
7.11
0.69
9.70%
Diluted Earnings per share
7.80
7.22
0.58
8.03%
Operating Profit Margin (Excl OI)
11.37%
9.91%
0.00
1.46%
Gross Profit Margin
11.02%
9.71%
0.00
1.31%
PAT Margin
7.49%
4.96%
0.00
2.53%
Public Share Holdings (%)
0.00%
0.00%
0.00
0.00%
Pledged Promotor Holding (%)
0.00%
0.00%
0.00
0.00%
Annual - Net Sales
Net Sales 189.63 Cr
in Mar 2026

Figures in Cr
stock-summary

YoY Growth in year ended Mar 2026 is 21.78% vs 14.78% in Mar 2025

Annual - Consolidate Net Profit
Consolidate Net Profit 12.15 Cr
in Mar 2026

Figures in Cr
stock-summary

YoY Growth in year ended Mar 2026 is 49.08% vs -27.88% in Mar 2025

Annual - Operating Profit (PBDIT)
Operating Profit (PBDIT) 21.56 Cr
in Mar 2026

Figures in Cr
stock-summary

YoY Growth in year ended Mar 2026 is 31.30% vs -11.39% in Mar 2025

Annual - Interest
Interest 2.80 Cr
in Mar 2026

Figures in Cr
stock-summary

YoY Growth in year ended Mar 2026 is -23.71% vs 67.58% in Mar 2025

Annual - Operating Profit Margin (Excl OI)
Operating Profit Margin (Excl OI) 11.37%
in Mar 2026

Figures in %
stock-summary

YoY Growth in year ended Mar 2026 has improved from Mar 2025